1. Home
  2. TRVG vs IPHA Comparison

TRVG vs IPHA Comparison

Compare TRVG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$4.39

Market Cap

197.0M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.77

Market Cap

189.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRVG
IPHA
Founded
2005
1999
Country
Germany
France
Employees
N/A
163
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.0M
189.5M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
TRVG
IPHA
Price
$4.39
$1.77
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$3.95
$5.75
AVG Volume (30 Days)
64.4K
134.2K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.59
$180.36
Revenue Next Year
$8.42
N/A
P/E Ratio
$16.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$1.18
52 Week High
$5.00
$2.63

Technical Indicators

Market Signals
Indicator
TRVG
IPHA
Relative Strength Index (RSI) 69.31 52.02
Support Level $2.78 $1.74
Resistance Level N/A $1.80
Average True Range (ATR) 0.32 0.08
MACD 0.08 -0.02
Stochastic Oscillator 75.00 30.43

Price Performance

Historical Comparison
TRVG
IPHA

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: